Response and Remission to Treatment With Anti-IL5/IL5R Antagonists

NCT06348173 · clinicaltrials.gov ↗

COMPLETED

Status

109

Enrollment

OTHER

Sponsor class

Conditions

Asthma

Interventions

DRUG: Mepolizumab

Sponsor

Université de Montréal

Collaborators

[object Object]